Trxade Health EBIT

The latest EBIT for MEDS is $-47B as of March 2026. That compares with $12M in the prior-year period — down 388771.3% year over year. That is below the Finance sector average of $300B. Investors often review this figure alongside Trxade Health's historical trend and sector peers before judging valuation or financial health.

Over the past year, MEDS's EBIT moved from $12M to $-47B — a 388771.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Trxade Health's operating scale or balance-sheet position.

Against Finance companies, MEDS currently prints $-47B for EBIT, while the sector average sits near $300B. That is roughly 115.8% below the sector mean. Large gaps often invite a closer look at Trxade Health's growth, margins, and balance sheet.

A EBIT figure of $-47B for MEDS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Finance average is about $300B. Explore the charts below for those layers of context.

After noting MEDS's EBIT ($-47B), review year-over-year change from $12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.